HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 06-15-2005, 08:23 AM   #1
Rich
Guest
 
Posts: n/a
http://www.smartmoney.com/stockwatch/index...?story=20050614

"Hauber suggests that some products toward the end of the GSK pipeline, including the breast and lung cancer drug Lapatinib, could be prone to setbacks because they were rushed through earlier research stages. She wrote that "significant miscalculations were made" in the development of Lapatinib and that "marketing considerations appear to have overruled preclinical insights, and Phase III trials were begun before data from (failed) pivotal Phase II studies became available." Her conclusion: "Ongoing Phase III studies have high risk of failure in our view, suggesting that the current submission target (2006/07) is too ambitious. Lapatinib may not reach the market in this decade." That would be a large blow to the GSK pipeline and to the company in general. "
  Reply With Quote
Old 06-16-2005, 03:04 PM   #2
*_Christine MH_*
Guest
 
Posts: n/a
And a great blow to cancer patients as well! Thank you for bringing this up. Alot of what is written about cancer drugs is written to lure investors, so there is a bit of hype involved and I think we need to be aware of it.
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 06:41 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter